News und Analysen

If you are looking for reliable dividend stocks that can provide steady income and growth in any market condition, you might want to consider these two blue chip companies that have proven their

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys

Income investors won't be happy with dividends that aren't sustainable. Instead, they want to own dividend stocks that they can depend on.

Three Motley Fool contributors identified stocks that

Shares of BioLife Solutions (NASDAQ: BLFS) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company's

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a

Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

As conventional investment wisdom has it, it's best to buy low and sell high. However, that only works when you have solid reasons to believe a company's shares will bounce back meaningfully after a

Value investing is a rather popular investing strategy. Seeing as almost everyone enjoys buying great products at discounted prices, it isn't surprising that we would also like to get good deals on

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries and

There's nothing like a surge in a deadly disease to encourage investors back into a noted healthcare stock. This dynamic benefited biotech Novavax (NASDAQ: NVAX) on Thursday.

It was also on the back

Shares of MacroGenics (NASDAQ: MGNX) were up more than 24% as of 11:45 a.m. on Thursday after the biotech company announced second-quarter earnings. The stock is down more than 7% so far this year.

Abbott Laboratories (NYSE: ABT) posted its latest earnings numbers last month, and there's reason to be optimistic about the business. Although a drop in COVID testing means sales are down overall

In the realm of investing, market capitalization is a good but not perfect way to gauge the success of a business. Sure, sometimes companies are overvalued. But a company's market value can at least

In the realm of investing, market capitalization is a good but not perfect way to gauge the success of a business. Sure, sometimes companies are overvalued. But a company's market value can at least

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's

Biogen (NASDAQ: BIIB) is an intriguing stock right now. Its business has struggled to generate growth in recent years, but some recent catalysts could turn things around. For starters, the company's